Drug Pricing

Voting for the U.S. presidential election is underway and one group of investors couldn't be more relieved that the end is in sight. As noted by Gadfly's Max Nisen, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has fallen 23 percent year-to-date while the Bloomberg...

Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) disclosed that it received a letter from Rep. Elijah Cummings (D-Md.) and Sen. Bernie Sanders (I-Vt.) seeking information on drug pricing. The company indicated that it would respond to the request. Both the leaders charged the drug firm of "repeated and...

Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.) delivered a letter to Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) President and CEO Paris Panayiotopoulos. The purpose of the letter is to request information as to why the company felt justified in boosting the price of its Iclusig (...

Drug pricing has been one of the central issues of the 2016 presidential campaign. There is currently a whirlwind of negative public sentiment swirling around controversial pricing practices of companies like Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Mallinckrodt PLC (NYSE: MNK) and Mylan NV (...

Presidential hopefuls Hillary Clinton and Donald Trump covered a lot of important issues during Monday night’s 1.5-hour debate. However, one issue that was not raised was the topic of prescription drug prices. In the past year, Clinton has specifically called out Valeant Pharmaceuticals Intl...

Brenton Saunders is the CEO and president of Allergan plc Ordinary Shares (NYSE: AGN), and on Tuesday, he clarified what he believes to be the core components of an already existing "social contract" with stakeholders. In a blog post, Saunders stated he understands the recent public outcry against...

Hillary Clinton, Democratic presidential nominee, introduced a new plan to address the "unjustified" price increases on life-savings drugs that have become commonplace among some drug makers over the past few years. According to Reuters, Clinton plans on creating an oversight panel that will be...

Mylan NV (NASDAQ: MYL), the seller of a potentially life-saving medical device called EpiPen, saw its share of controversy this week when officials of the U.S. government called into question the company's pricing policies. In 2008, the EpiPen sold for around $100 but has since risen six...

Mylan NV (NASDAQ: MYL)'s 400 percent price hike to a potentially life-saving device was called into question by members of the U.S. government this week. Mylan, the maker of EpiPen, an epinephrine auto injector used in emergency cases by individuals suffering a severe allergic reaction,...

Mark Cuban, the famed billionaire entrepreneur and owner of the NBA's Dallas Maverick, tweeted his support for drug pricing controls on Monday. He stated, "Empathy arbitrage can not be a pricing strategy." In a response to a follower, Cuban added "innovation won't decline" when companies lose out...

Senator Susan Collins (R-Maine) was a guest on Bloomberg Markets to discuss Valeant Pharmaceuticals Intl Inc (NYSE: VRX) senate hearings into its drug pricing policies. The Bloomberg hosts pointed out that Bill Ackman, a major Valeant shareholder and board member, has an impressive track record...

David Maris is an analyst at Wells Fargo that initiated coverage of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) with a Sell rating back in February. On Wednesday, he was a guest on CNBC's Halftime Report segment to discuss his views on the company. Maris began by saying that appointing Joe Pappa...

Democratic Presidential candidate Hillary Clinton released a new video ad on Monday directly attacking Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s drug pricing policies. Clinton's video ad, which was uploaded to her YouTube profile, was viewed just 200 times by mid-Tuesday morning...

In a new report, Evercore ISI analyst Terry Haines discussed the potential for some form of drug pricing legislation in the U.S. within the next two years. The SPDR S&P Biotech (ETF) (NYSE: XBI) is down 35.3 percent in the past six months since Democratic presidential front-runner Hillary...